Login / Signup

Tumor hypoxia and role of hypoxia-inducible factor in oral cancer.

Pooja SinghMonika RajputManoj Pandey
Published in: World journal of surgical oncology (2024)
Hypoxia is common in HNC and can be detected by use of biomarkers. The tumors that show expression of hypoxia biomarkers have poor prognosis except for patients with human papilloma virus-associated or VHL-associated cancers. Therapeutic targeting of hypoxia is emerging; however, it is still in its nascent stage, with increasing clinical trials hypoxia is set to emerge as an attractive therapeutic target in HNC.
Keyphrases
  • poor prognosis
  • endothelial cells
  • long non coding rna
  • clinical trial
  • randomized controlled trial
  • cancer therapy
  • open label
  • phase ii